2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS
申请人:Wan Zehong
公开号:US20140179715A1
公开(公告)日:2014-06-26
Disclosed are 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one compounds that inhibit Lp-PLA
2
, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA
2
, for example atherosclerosis, Alzheimer's disease.
申请人:GlaxoSmithKline Intellectual Property Development Limited
公开号:US10125141B2
公开(公告)日:2018-11-13
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2
申请人:GlaxoSmithKline Intellectual Property Development
Limited
公开号:EP3172211B1
公开(公告)日:2019-07-03
COMPOUNDS
申请人:GlaxoSmithKline Intellectual Property Development Limited
公开号:US20190023715A1
公开(公告)日:2019-01-24
The present invention relates to novel compounds that inhibit Lp-PLA
2
activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA
2
, for example Alzheimer's disease.